Exscientia expands translational capabilities with Allcyte acquisition
Allcyte specialises in artificial intelligence (AI) based precision medicine
Read More
Tag: Exscientia
Alzheimer’s drug designed using Exscientia’s AI technology enters clinic
Drug candidate is being evaluated for the treatment of Alzheimer’s disease psychosis
Read More
Human trials for world’s first AI-designed immuno-oncology drug
The drug was discovered through an AI-design platform within just eight months of project initiation
Read More
Oxford University to develop Alzheimer’s disease treatments with Exscientia
Exscientia will use its AI-driven technology to generate novel clinical assets targeting neuroinflammation
Read More
Celgene and Exscientia ink three year AI drug discovery collaboration
Exscientia has announced a three-year drug discovery AI collaboration with Celgene.
Read More
GSK signs drug discovery pact with AI group Exscientia
GlaxoSmithKline has signed a drug discovery pact with Dundee, UK-based artificial intelligence (AI) group Exscientia focused on multiple therapeutic areas.
Read More
Sanofi, Exscientia link to develop bispecific small molecule drugs
Dundee, Scotland-based artificial intelligence group Exscientia has signed a research collaboration and licence option agreement with Sanofi focusing on the “high-interest area of metabolic disease”.
Read More
- MIT’s new MRI brain light-detecting technique could support brain cell studies
- PharmaTimes MSEA and NIEA awards are open for entry
- BBSRC invests £48m in Babraham Institute to advance lifelong health research
- NHS reduces long waits for cancer care and achieves faster ambulance responses
- MHRA’s AI Airlock to address challenges for regulating AI medical devices
